The collective work of scientists from the Cancer Center at Johns Hopkins, the University of Texas at San Antonio and the University of Wisconsin to develop a new cancer drug, has given good results. In their study, researchers used a toxic substance thapsigargin obtained from Thapsia garganica Mediterranean plant weed. On its lethal properties were known at the time of Ancient Greek civilization, and the Arab caravans mushers this plant was was strictly forbidden, as the plants die from camels.
In laboratory studies, the researchers received the drug. The original name of the drug G202 and its action has been tried on mice that were implanted with cancer cells taken from humans. Tumor within 30 days of the order grew by 50 percent, and after a week (or so) in animals came the inevitable death. When injected into the blood of mice, a new drug for three days, it was observed for 21 days a significant decrease "epicenter" of the tumor exactly half. These results even exceeded the ability of chemotherapeutic agents dotsetakseloma to destroy cancer cells.
The principle of action of this drug belongs to the category of innovation. The drug is injected into the blood, and he travels in the bloodstream, and the immune cells do not notice it. In blood vessels, it "catches" proteins that are specific for the metabolism of cancer cells, and proceeds to the destruction of tissues and cells, which supply blood to the tumor and nutrients, while sparing healthy vessels and tissue.
John Isaacs — the lead researcher, Professor of Urology, Oncology, Biomedical and Chemical Engineering at Johns Hopkins University, Ph.D. states: "The action of the drug G202 is very similar to the effect of a bomb at the molecular level." Journal «Science Translational Medicine» has published the results of the 2nd stage of research.
Studies were conducted on cancer cells that are found in the breast, bladder, and kidney. It turned out that the resulting formulation produces 50 percent regression in the development of the above tumor formation. On the 3rd stage will involve 29 patients with advanced cancers detected above bodies.
By Elena Kravetz